Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2,414.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 297,881 shares of the company’s stock after buying an additional 286,034 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Novo Nordisk A/S were worth $14,280,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Certuity LLC boosted its holdings in Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after acquiring an additional 177 shares during the last quarter. Oakworth Capital Inc. increased its stake in Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. Werba Rubin Papier Wealth Management raised its holdings in shares of Novo Nordisk A/S by 6.0% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 4,270 shares of the company’s stock worth $217,000 after purchasing an additional 241 shares during the period. Finally, CoreCap Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock valued at $256,000 after purchasing an additional 242 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Novo Nordisk A/S Stock Up 0.8%

NYSE NVO opened at $46.75 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The business has a 50 day moving average price of $47.30 and a two-hundred day moving average price of $44.50. The stock has a market cap of $208.74 billion, a PE ratio of 11.43, a P/E/G ratio of 4.23 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s payout ratio is 42.79%.

Analysts Set New Price Targets

Several research analysts recently commented on NVO shares. Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a report on Wednesday. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. BMO Capital Markets reissued a “market perform” rating and issued a $47.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Finally, HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Four research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.